NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 30 01:33PM ET
1.84
Dollar change
-0.09
Percentage change
-4.66
%
IndexRUT P/E- EPS (ttm)-3.00 Insider Own54.61% Shs Outstand49.72M Perf Week-1.08%
Market Cap92.26M Forward P/E- EPS next Y-1.33 Insider Trans-0.13% Shs Float22.76M Perf Month26.90%
Income-147.27M PEG- EPS next Q-0.36 Inst Own35.69% Short Float6.69% Perf Quarter-5.64%
Sales0.00M P/S- EPS this Y54.67% Inst Trans-4.54% Short Ratio7.10 Perf Half Y1.66%
Book/sh3.11 P/B0.59 EPS next Y2.21% ROA-54.84% Short Interest1.52M Perf Year-85.61%
Cash/sh3.42 P/C0.54 EPS next 5Y22.34% ROE-70.13% 52W Range1.34 - 16.31 Perf YTD-11.11%
Dividend Est.- P/FCF- EPS past 5Y-166.47% ROI-83.95% 52W High-88.72% Beta0.77
Dividend TTM- Quick Ratio10.84 Sales past 5Y0.00% Gross Margin- 52W Low37.31% ATR (14)0.10
Dividend Ex-Date- Current Ratio10.84 EPS Y/Y TTM1.27% Oper. Margin- RSI (14)59.98 Volatility4.51% 7.16%
Employees14 Debt/Eq0.16 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.14 EPS Q/Q11.91% Payout- Rel Volume0.89 Prev Close1.93
Sales Surprise- EPS Surprise-108.14% Sales Q/Q- EarningsMar 28 AMC Avg Volume214.49K Price1.84
SMA2010.48% SMA507.70% SMA2000.92% Trades Volume123,003 Change-4.66%
Date Action Analyst Rating Change Price Target Change
Jul-09-24Downgrade Stifel Buy → Hold $34 → $3
Jul-09-24Downgrade Leerink Partners Outperform → Market Perform $28 → $2
Jul-09-24Downgrade H.C. Wainwright Buy → Neutral $28 → $2
Jul-08-24Downgrade JP Morgan Overweight → Neutral $24 → $5
Jul-08-24Downgrade Guggenheim Buy → Neutral
Dec-13-23Initiated H.C. Wainwright Buy $28
Mar-28-25 05:00PM
Nov-07-24 08:00AM
Oct-14-24 12:00PM
Aug-08-24 07:20PM
Aug-01-24 11:53AM
04:00PM Loading…
Jul-31-24 04:00PM
Jul-29-24 09:35AM
Jul-11-24 09:35AM
Jul-09-24 10:19AM
Jul-08-24 12:36PM
12:17PM
08:42AM
08:16AM
07:30AM
May-23-24 02:15AM
02:26PM Loading…
May-10-24 02:26PM
May-09-24 11:55PM
04:05PM
Apr-14-24 12:52PM
Apr-06-24 01:33AM
Mar-21-24 02:32AM
Mar-20-24 09:53PM
04:00PM
Mar-08-24 11:55PM
Feb-22-24 11:27PM
Feb-05-24 04:05PM
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
Dec-19-23 01:01PM
09:48PM Loading…
Dec-05-23 09:48PM
Nov-30-23 09:55AM
Nov-21-23 11:03AM
Nov-14-23 12:00PM
09:55AM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
Sep-19-23 08:05PM
04:09PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
07:00AM
Jun-07-23 09:55AM
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HERSHBERG ROBERTSee RemarksFeb 04 '25Sale1.8914,63427,6581,113,399Feb 12 04:05 PM
HERSHBERG ROBERTSee RemarksFeb 11 '25Sale1.7611,90121,0031,101,498Feb 12 04:05 PM
Maltbie ShaneChief Financial OfficerFeb 11 '25Sale1.764,3457,65979,887Feb 12 04:05 PM
Maltbie ShaneChief Financial OfficerFeb 04 '25Sale1.893,9467,45884,232Feb 12 04:05 PM
Kohli AdityaDirectorMay 20 '24Sale15.456,00092,689776,878May 22 05:40 PM
Kohli AdityaDirectorMay 22 '24Sale14.736,00088,372764,878May 22 05:40 PM
Kohli AdityaDirectorMay 21 '24Sale14.216,00085,230770,878May 22 05:40 PM
Kohli AdityaDirectorMay 02 '24Sale14.016,00084,081783,601May 03 07:12 PM
Kohli AdityaDirectorMay 03 '24Sale14.1572310,233782,878May 03 07:12 PM
Kohli AdityaDirectorMay 01 '24Sale14.031752,456789,601May 03 07:12 PM